IRIDEX Corporation (IRIX): Price and Financial Metrics
IRIX Price/Volume Stats
Current price | $2.35 | 52-week high | $3.48 |
Prev. close | $2.41 | 52-week low | $1.31 |
Day low | $2.31 | Volume | 49,900 |
Day high | $2.47 | Avg. volume | 25,715 |
50-day MA | $2.71 | Dividend yield | N/A |
200-day MA | $2.36 | Market Cap | 38.18M |
IRIX Stock Price Chart Interactive Chart >
IRIX POWR Grades
- Value is the dimension where IRIX ranks best; there it ranks ahead of 81.33% of US stocks.
- The strongest trend for IRIX is in Growth, which has been heading up over the past 78 days.
- IRIX ranks lowest in Momentum; there it ranks in the 4th percentile.
IRIX Stock Summary
- IRIX has a market capitalization of $45,168,920 -- more than approximately just 13.48% of US stocks.
- The capital turnover (annual revenue relative to shareholder's equity) for IRIX is 4.53 -- better than 89.5% of US stocks.
- For IRIX, its debt to operating expenses ratio is greater than that reported by just 13.83% of US equities we're observing.
- If you're looking for stocks that are quantitatively similar to IRIDEX CORP, a group of peers worth examining would be APDN, BDC, CMCM, FLUX, and ECOR.
- IRIX's SEC filings can be seen here. And to visit IRIDEX CORP's official web site, go to www.iridex.com.
IRIX Valuation Summary
- In comparison to the median Healthcare stock, IRIX's price/sales ratio is 63.64% lower, now standing at 0.8.
- Over the past 243 months, IRIX's price/sales ratio has gone down 0.4.
Below are key valuation metrics over time for IRIX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
IRIX | 2023-12-29 | 0.8 | 3.8 | -5.9 | -5.3 |
IRIX | 2023-12-28 | 0.8 | 3.7 | -5.7 | -5.1 |
IRIX | 2023-12-27 | 0.8 | 3.5 | -5.4 | -4.8 |
IRIX | 2023-12-26 | 0.7 | 3.4 | -5.3 | -4.6 |
IRIX | 2023-12-22 | 0.8 | 3.5 | -5.4 | -4.8 |
IRIX | 2023-12-21 | 0.8 | 3.5 | -5.4 | -4.8 |
IRIX Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -168.35%.
- The 4 year net income to common stockholders growth rate now stands at 45.79%.
- Its 4 year revenue growth rate is now at -6.35%.
The table below shows IRIX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 57.031 | -9.667 | -8.842 |
2022-06-30 | 55.66 | -8.205 | -9.24 |
2022-03-31 | 55.331 | -6.866 | -5.606 |
2021-12-31 | 53.903 | 8.217 | -5.225 |
2021-09-30 | 50.953 | 9.747 | -2.961 |
2021-06-30 | 46.492 | 10.801 | -2.515 |
IRIX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IRIX has a Quality Grade of B, ranking ahead of 78.49% of graded US stocks.
- IRIX's asset turnover comes in at 1.188 -- ranking 15th of 186 Medical Equipment stocks.
- STXS, FONR, and SMLR are the stocks whose asset turnover ratios are most correlated with IRIX.
The table below shows IRIX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-07-03 | 1.188 | 0.436 | -0.221 |
2021-04-03 | 1.162 | 0.422 | -0.575 |
2021-01-02 | 1.247 | 0.428 | -0.493 |
2020-09-26 | 1.160 | 0.414 | -0.559 |
2020-06-27 | 1.151 | 0.410 | -0.513 |
2020-03-28 | 1.195 | 0.420 | -0.474 |
IRIX Price Target
For more insight on analysts targets of IRIX, see our IRIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $10.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
IRIDEX Corporation (IRIX) Company Bio
IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. The company was founded in 1989 and is based in Mountain View, California.
Latest IRIX News From Around the Web
Below are the latest news stories about IRIDEX CORP that investors may wish to consider to help them evaluate IRIX as an investment opportunity.
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of CyclophotocoagulationMOUNTAIN VIEW, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful advocacy for revision of the recently issued Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation (CPC). During the last few days, the five Medicare Administrative Contractors (MACs) t |
Iridex Reports Third Quarter 2023 Financial Results and Business UpdateMOUNTAIN VIEW, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. Recent Business Updates Generated total revenue of $12.9 million, representing flat sequential quarter revenue and a decre |
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023The Company also announced plans to present at Stifel Healthcare ConferenceMOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, N |
Iridex to Report Third Quarter Financial Results on November 14, 2023MOUNTAIN VIEW, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 14, 2023. About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical sy |
IRIDEX's (NASDAQ:IRIX) growing losses don't faze investors as the stock surges 18% this past weekOne simple way to benefit from the stock market is to buy an index fund. But many of us dare to dream of bigger... |
IRIX Price Returns
1-mo | -10.65% |
3-mo | -9.96% |
6-mo | 7.06% |
1-year | 16.92% |
3-year | -68.11% |
5-year | -45.60% |
YTD | -16.37% |
2023 | 39.80% |
2022 | -67.10% |
2021 | 143.43% |
2020 | 12.56% |
2019 | -52.55% |
Continue Researching IRIX
Want to do more research on Iridex Corp's stock and its price? Try the links below:Iridex Corp (IRIX) Stock Price | Nasdaq
Iridex Corp (IRIX) Stock Quote, History and News - Yahoo Finance
Iridex Corp (IRIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...